Summary & Overview
HCPCS J9223: Injection, lurbinectedin, 0.1 mg
HCPCS Level II code J9223 denotes the injectable oncology drug lurbinectedin, billed per 0.1 mg increment. This code is used to capture drug acquisition costs and dosing units for patients receiving lurbinectedin infusions, typically in outpatient infusion centers or hospital outpatient departments. Accurate reporting of this code matters nationally because oncology drug billing drives treatment cost accounting, payer coverage determinations, and clinical cost reporting across commercial and public payers.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a practical overview of what J9223 represents clinically and operationally, plus the typical settings for administration. The publication summarizes national benchmarking expectations, common modifier usage (listed separately), and policy considerations that affect reimbursement and claim adjudication. It also highlights clinical context for lurbinectedin dosing and documentation points relevant to coverage reviews.
The content is intended to inform billing managers, revenue cycle leaders, and oncology clinical administrators about code definition, service implications, and the payer landscape so they can align charge capture, claims submission, and policy monitoring for this injectable antineoplastic agent.
Billing Code Overview
HCPCS Level II code J9223 describes the injection of lurbinectedin, 0.1 mg. This billing code represents a parenteral oncology drug administration where the billed item is the medication dose measured in 0.1 mg units. The service type is intravenous/injectable chemotherapy agent administration. The typical site of service for this drug is an outpatient infusion center or hospital outpatient department, where antineoplastic agents are commonly administered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with metastatic small cell lung cancer or another malignancy for which lurbinectedin is indicated after prior therapy. The patient presents to an outpatient oncology infusion center for administration of intravenous J9223 (lurbinectedin), billed per 0.1 mg units. Clinical workflow includes verification of diagnosis and prior authorization, chemotherapy order entry and dose calculation by the oncologist and oncology pharmacist, baseline labs (CBC, CMP) and assessment of performance status, insertion or assessment of intravenous access (peripheral IV or central venous catheter/port), premedication if indicated, administration over the recommended infusion time, monitoring for infusion reactions and cytopenias during and after infusion, documentation of lot number and units administered for drug accountability, and scheduling of follow-up visits and laboratory monitoring. Typical site of service is an outpatient hospital infusion center or freestanding oncology infusion clinic. Common accompanying activities include vital signs monitoring, antiemetic administration, IV access care, and toxicity assessment with dose adjustments as needed.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered | Use when part of the reconstituted or prepared lurbinectedin dose is discarded and the discarded amount must be reported for compliance or inventory; indicates discarded medication due to partial vial waste. |